Gene Transfection of Hepatocyte Growth Factor Attenuates Reperfusion Injury in the Heart

Overview

Journal Ann Thorac Surg

Publisher Elsevier

Specialties General Surgery
Pulmonary Medicine

Date 1999 Jul 3

PMID 10391282

Citations 11

Authors

H Ueda

Y Sawa

K Matsumoto

Y Kawahira

T Nakamura

Y Kaneda

H Matsuda

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocyte growth factor (HGF), a ligand for the c-Met receptor tyrosine kinase, plays a role as organotrophic factor for regeneration of various organs. HGF has an angiogenic activity and exhibits a potent antiapoptotic activity in several types of cells. Although HGF and the c-Met/HGF receptor are expressed in the heart, the role of HGF in the heart has remained unknown.

Methods: After we analyzed changes in expression of endogenous HGF and c-Met mRNA levels in the rat left ventricle after myocardial infarction, the human HGF gene in hemagglutinating virus of Japan (HVJ)-liposome was transfected into the normal whole rat heart. Three days after transfection, the heart was subjected to global warm ischemia and subsequent reperfusion, followed by assessment of its cardiac functions.

Results: Both HGF and c-Met/HGF receptor mRNAs were expressed in adult rat heart, and c-Met/HGF receptor mRNA was upregulated in response to myocardial infarction. HGF-transfected heart showed significant increase of human HGF protein level in the heart. Cardiac functions in terms of the left ventricular developed pressure, maximum dp/dt, and pressure rate product in hearts with HGF gene transfection were significantly superior to those in control hearts. In addition, leakage of creatine phosphokinase in the coronary artery effluent in hearts with HGF gene transfection was significantly lower than that in control hearts.

Conclusions: These data indicated that both HGF and c-Met/HGF receptor mRNAs were upregulated in response to myocardial ischemic injury, and that HGF is likely to have a cytoprotective effect on cardiac tissue, presumably through the c-Met/HGF receptor.

Citing Articles

Cardiac gene delivery using ultrasound: State of the field.

Singh D, Memari E, He S, Yusefi H, Helfield B Mol Ther Methods Clin Dev. 2024; 32(3):101277.

PMID: 38983873 PMC: 11231612. DOI: 10.1016/j.omtm.2024.101277.

and cooperate to protect skeletal muscle stem cells against inflammation-induced damage during regeneration.

Lahmann I, Griger J, Chen J, Zhang Y, Schuelke M, Birchmeier C Elife. 2021; 10.

PMID: 34350830 PMC: 8370772. DOI: 10.7554/eLife.57356.

Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety.

Ido A, Moriuchi A, Numata M, Murayama T, Teramukai S, Marusawa H J Transl Med. 2011; 9:55.

PMID: 21548996 PMC: 3112439. DOI: 10.1186/1479-5876-9-55.

A mouse model for spatial and temporal expression of HGF in the heart.

Riess I, Sala V, Leo C, Demaria M, Gatti S, Gallo S Transgenic Res. 2011; 20(6):1203-16.

PMID: 21360304 DOI: 10.1007/s11248-011-9485-y.

Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.

Ko Y, Falcao C, Torchilin V Mol Pharm. 2009; 6(3):971-7.

PMID: 19317442 PMC: 2705994. DOI: 10.1021/mp900006h.